324 related articles for article (PubMed ID: 28799202)
1. Immune tolerance induced by platelet-targeted factor VIII gene therapy in hemophilia A mice is CD4 T cell mediated.
Chen Y; Luo X; Schroeder JA; Chen J; Baumgartner CK; Hu J; Shi Q
J Thromb Haemost; 2017 Oct; 15(10):1994-2004. PubMed ID: 28799202
[TBL] [Abstract][Full Text] [Related]
2. The impact of GPIbα on platelet-targeted FVIII gene therapy in hemophilia A mice with pre-existing anti-FVIII immunity.
Chen J; Schroeder JA; Luo X; Montgomery RR; Shi Q
J Thromb Haemost; 2019 Mar; 17(3):449-459. PubMed ID: 30609275
[TBL] [Abstract][Full Text] [Related]
3. In vivo enrichment of genetically manipulated platelets corrects the murine hemophilic phenotype and induces immune tolerance even using a low multiplicity of infection.
Schroeder JA; Chen Y; Fang J; Wilcox DA; Shi Q
J Thromb Haemost; 2014 Aug; 12(8):1283-93. PubMed ID: 24931217
[TBL] [Abstract][Full Text] [Related]
4. Platelet gene therapy corrects the hemophilic phenotype in immunocompromised hemophilia A mice transplanted with genetically manipulated human cord blood stem cells.
Shi Q; Kuether EL; Chen Y; Schroeder JA; Fahs SA; Montgomery RR
Blood; 2014 Jan; 123(3):395-403. PubMed ID: 24269957
[TBL] [Abstract][Full Text] [Related]
5. The important role of von Willebrand factor in platelet-derived FVIII gene therapy for murine hemophilia A in the presence of inhibitory antibodies.
Shi Q; Schroeder JA; Kuether EL; Montgomery RR
J Thromb Haemost; 2015 Jul; 13(7):1301-9. PubMed ID: 25955153
[TBL] [Abstract][Full Text] [Related]
6. Lentivirus-mediated platelet gene therapy of murine hemophilia A with pre-existing anti-factor VIII immunity.
Kuether EL; Schroeder JA; Fahs SA; Cooley BC; Chen Y; Montgomery RR; Wilcox DA; Shi Q
J Thromb Haemost; 2012 Aug; 10(8):1570-80. PubMed ID: 22632092
[TBL] [Abstract][Full Text] [Related]
7. Pre-existing anti-factor VIII immunity alters therapeutic platelet-targeted factor VIII engraftment following busulfan conditioning through cytotoxic CD8 T cells.
Jing W; Baumgartner CK; Xue F; Schroeder JA; Shi Q
J Thromb Haemost; 2023 Mar; 21(3):488-498. PubMed ID: 36696197
[TBL] [Abstract][Full Text] [Related]
8. Platelet-Targeted FVIII Gene Therapy Restores Hemostasis and Induces Immune Tolerance for Hemophilia A.
Cai Y; Shi Q
Front Immunol; 2020; 11():964. PubMed ID: 32595633
[TBL] [Abstract][Full Text] [Related]
9. Long-term tolerance to factor VIII is achieved by administration of interleukin-2/interleukin-2 monoclonal antibody complexes and low dosages of factor VIII.
Liu CL; Ye P; Lin J; Djukovic D; Miao CH
J Thromb Haemost; 2014 Jun; 12(6):921-31. PubMed ID: 24684505
[TBL] [Abstract][Full Text] [Related]
10. Syngeneic transplantation of hematopoietic stem cells that are genetically modified to express factor VIII in platelets restores hemostasis to hemophilia A mice with preexisting FVIII immunity.
Shi Q; Fahs SA; Wilcox DA; Kuether EL; Morateck PA; Mareno N; Weiler H; Montgomery RR
Blood; 2008 Oct; 112(7):2713-21. PubMed ID: 18495954
[TBL] [Abstract][Full Text] [Related]
11. The immunogenicity of platelet-derived FVIII in hemophilia A mice with or without preexisting anti-FVIII immunity.
Chen Y; Schroeder JA; Chen J; Luo X; Baumgartner CK; Montgomery RR; Hu J; Shi Q
Blood; 2016 Mar; 127(10):1346-54. PubMed ID: 26668132
[TBL] [Abstract][Full Text] [Related]
12. Anti-CD3 antibodies modulate anti-factor VIII immune responses in hemophilia A mice after factor VIII plasmid-mediated gene therapy.
Peng B; Ye P; Rawlings DJ; Ochs HD; Miao CH
Blood; 2009 Nov; 114(20):4373-82. PubMed ID: 19770362
[TBL] [Abstract][Full Text] [Related]
13. CD4
Fu RY; Chen AC; Lyle MJ; Chen CY; Liu CL; Miao CH
Cell Immunol; 2020 Dec; 358():104216. PubMed ID: 32987195
[TBL] [Abstract][Full Text] [Related]
14. CD4+FOXP3+ regulatory T cells confer long-term regulation of factor VIII-specific immune responses in plasmid-mediated gene therapy-treated hemophilia mice.
Miao CH; Harmeling BR; Ziegler SF; Yen BC; Torgerson T; Chen L; Yau RJ; Peng B; Thompson AR; Ochs HD; Rawlings DJ
Blood; 2009 Nov; 114(19):4034-44. PubMed ID: 19713458
[TBL] [Abstract][Full Text] [Related]
15. Lentivirus-mediated platelet-derived factor VIII gene therapy in murine haemophilia A.
Shi Q; Wilcox DA; Fahs SA; Fang J; Johnson BD; DU LM; Desai D; Montgomery RR
J Thromb Haemost; 2007 Feb; 5(2):352-61. PubMed ID: 17269937
[TBL] [Abstract][Full Text] [Related]
16. B Cell Depletion Eliminates FVIII Memory B Cells and Enhances AAV8-coF8 Immune Tolerance Induction When Combined With Rapamycin.
Biswas M; Palaschak B; Kumar SRP; Rana J; Markusic DM
Front Immunol; 2020; 11():1293. PubMed ID: 32670285
[TBL] [Abstract][Full Text] [Related]
17. In vivo expansion of regulatory T cells with IL-2/IL-2 mAb complexes prevents anti-factor VIII immune responses in hemophilia A mice treated with factor VIII plasmid-mediated gene therapy.
Liu CL; Ye P; Yen BC; Miao CH
Mol Ther; 2011 Aug; 19(8):1511-20. PubMed ID: 21468007
[TBL] [Abstract][Full Text] [Related]
18. Targeting factor VIII expression to platelets for hemophilia A gene therapy does not induce an apparent thrombotic risk in mice.
Baumgartner CK; Mattson JG; Weiler H; Shi Q; Montgomery RR
J Thromb Haemost; 2017 Jan; 15(1):98-109. PubMed ID: 27496751
[TBL] [Abstract][Full Text] [Related]
19. Induction of tolerance to factor VIII by transient co-administration with rapamycin.
Moghimi B; Sack BK; Nayak S; Markusic DM; Mah CS; Herzog RW
J Thromb Haemost; 2011 Aug; 9(8):1524-33. PubMed ID: 21585650
[TBL] [Abstract][Full Text] [Related]
20. Transient blockade of the inducible costimulator pathway generates long-term tolerance to factor VIII after nonviral gene transfer into hemophilia A mice.
Peng B; Ye P; Blazar BR; Freeman GJ; Rawlings DJ; Ochs HD; Miao CH
Blood; 2008 Sep; 112(5):1662-72. PubMed ID: 18574023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
